
Photo: Magdalena Wiklund via Flickr
By forcing the Food and Drug Administration on Aug. 23 to approve blood plasma as a COVID-19 treatment under an emergency use authorization (EUA), President Trump again inserted politics into scientific research ― a situation that may create even more uncertainty about plasma as a potential treatment.
Plasma ― the part of blood that contains antibodies and proteins ― is still under investigation for this use, and those leading randomized clinical trials now far they may have difficulty recruiting new patients due to the controversy.